Cited 0 times in Scipus Cited Count

Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases

DC Field Value Language
dc.contributor.authorKim, JW-
dc.contributor.authorJung, JY-
dc.contributor.authorKim, HA-
dc.contributor.authorSon, H-
dc.contributor.authorSuh, CH-
dc.date.accessioned2024-06-19T07:07:12Z-
dc.date.available2024-06-19T07:07:12Z-
dc.date.issued2024-
dc.identifier.issn0032-5473-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32567-
dc.description.abstractPurpose: We evaluated the preference, patient satisfaction, and efficacy of zoledronic acid compared with oral bisphosphonates (BPs) for glucocorticoid-induced osteoporosis (GIOP) in patients with autoimmune diseases. Methods: We enrolled 50 patients with new fractures or osteoporosis detected on follow-up bone densitometry after at least 1 year of oral BP use among patients diagnosed with GIOP during treatment for autoimmune diseases. After 1 year of zoledronic acid treatment, patients completed a survey for preference and satisfaction assessment. Treatment efficacy was analysed by comparing bone mineral density changes and fractures with those in a control group of patients who continued oral BP use. Results: Age, sex, treatment duration, and medication history did not differ significantly between the two groups. Among the participants, 86.7% preferred and were more satisfied with intravenous zoledronic acid than with oral BPs, primarily because of the convenience of its administration interval. Only two patients (4%) reported infusion-related adverse events with zoledronic acid. Furthermore, no significant differences were observed in the annualized percentage change in the bone mineral density of the lumbar spine, femur neck, and hip between patients receiving zoledronic acid and those receiving oral BPs. The occurrence of new fractures was consistent across both groups, with two cases in each, showing no significant differences. Conclusion: Patients showed a preference for and greater satisfaction with zoledronic acid, and its efficacy in treating osteoporosis was comparable to that of oral BPs. Therefore, zoledronic acid is a suitable treatment option for GIOP in patients with autoimmune diseases.-
dc.language.isoen-
dc.subject.MESHAdministration, Oral-
dc.subject.MESHAged-
dc.subject.MESHAutoimmune Diseases-
dc.subject.MESHBone Density Conservation Agents-
dc.subject.MESHBone Density-
dc.subject.MESHDiphosphonates-
dc.subject.MESHFemale-
dc.subject.MESHGlucocorticoids-
dc.subject.MESHHumans-
dc.subject.MESHImidazoles-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOsteoporosis-
dc.subject.MESHPatient Preference-
dc.subject.MESHPatient Satisfaction-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHZoledronic Acid-
dc.titlePatient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases-
dc.typeArticle-
dc.identifier.pmid38297995-
dc.subject.keywordautoimmune diseases-
dc.subject.keywordglucocorticoid-induced osteoporosis-
dc.subject.keywordpatient preference-
dc.subject.keywordtreatment efficacy-
dc.subject.keywordzoledronic acid-
dc.contributor.affiliatedAuthorKim, JW-
dc.contributor.affiliatedAuthorJung, JY-
dc.contributor.affiliatedAuthorKim, HA-
dc.contributor.affiliatedAuthorSuh, CH-
dc.type.localJournal Papers-
dc.identifier.doi10.1093/postmj/qgae003-
dc.citation.titlePostgraduate medical journal-
dc.citation.volume100-
dc.citation.number1183-
dc.citation.date2024-
dc.citation.startPage334-
dc.citation.endPage341-
dc.identifier.bibliographicCitationPostgraduate medical journal, 100(1183). : 334-341, 2024-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1469-0756-
dc.relation.journalidJ000325473-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse